From Nemaura’s new Oceania distribution deal to Sanuwave’s promissory note expansion, here are seven medtech stories we missed this week but thought were still worth mentioning.
1. Nemaura inks Oceania distribution deal for SugarBeat patch
Nemaura announced in an Aug. 15 press release that it has signed a non-binding distribution deal with Device Technologies for exclusive rights to market the SugarBeat glucose monitoring system in Australia and New Zealand. The SugarBeat is a disposable, adhesive skin patch that is used by diabetics, providing a non-invasive and needle-free method of continuous glucose monitoring. Device Technologies is a medical device distributor in Australia and New Zealand. Nemaura Medical is expected to launch its product in Australia and New Zealand as early as 2018 after its 2017 launch in the U.K.
2. Korea approves Meere’s Revo-i surgical robotic system
The Korean Ministry of Food and Drug Safety announced that it has approved Korea’s first surgical robot, according to an Aug. 3 press release. The robot, Revo-i, helps perform minimally-invasive surgery. It was developed by the Korean biotech firm Meere Co. and can be used in operating rooms for endoscopic surgical procedures like cholecystectomy and prostatectomy.
3. Si-Bone touts iFuse study data
Sib-Bone announced in an Aug. 9 press release that the SI joint can be diagnosed as a cause of lower back pain and the presence of pain localized over the posterior superior iliac spine. The study was designed to outline the diagnostic value of signs and symptoms for primary care without needing more expensive and invasive tests. The study reports that the clinical prediction rule for the diagnosis of SI joint pain (in a cluster of three to five positive provocative maneuvers without known discogenic or radicular pain) and dominant pain localized on the posterior superior iliac spine are as good as or better than clinical prediction rules designed for other lumbar spine conditions.